Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 32

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 3
Chunk 32
---
 To comply with this statute, we are required to document and test our internal control over financial reporting. Our efforts to comply with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, governing internal control and procedures for financial reporting, have resulted in increased general and administrative expenses and a diversion of management time and attention, and we expect these efforts to require the continued commitment of significant resources. We may identify material weaknesses or significant deficiencies in our assessments of our internal control over financial reporting. Failure to maintain effective internal control over financial reporting, or conclusion that our disclosure controls and procedures are ineffective, could result in investigations or sanctions by regulatory authorities and could adversely affect our operating results, investor confidence in our reported financial information, and the market price of our ordinary shares and ADSs.

Risks Related to Ownership of Our Securities

Our stock price may be volatile and the trading market for our securities is limited.

The market price for our securities, like that of the securities of other pharmaceutical and biotechnology companies, has fluctuated substantially and may continue to be highly volatile in the future. The market price for our securities has been affected by both broad market developments and announcements relating to actual or potential developments concerning products under development. We believe that the following factors, in addition to other risk factors described above and elsewhere in this annual report, will continue to significantly affect the market price of our ordinary shares:

●   the results of pre-clinical testing and clinical trials by us and our competitors;
--------------------------------------------------------------------------------------

●   developments concerning research and development, manufacturing, and marketing alliances or collaborations by us and our competitors;
-----------------------------------------------------------------------------------------------------------------------------------------

●   announcements of technological innovations or new commercial products by us and our competitors;
----------------------------------------------------------------------------------------------------

●   determinations regarding our patent applications, patents and those of others;
----------------------------------------------------------------------------------

●        publicity regarding actual or potential results relating     
    to medicinal products under development by us and our competitors;
----------------------------------------------------------------------

●   proposed governmental regulations and developments in Australia,
                        the U.S. and elsewhere;                     
--------------------------------------------------------------------

●   litigation;
---------------

●   economic and other external factors; and
--------------------------------------------

●   period-to-period fluctuations in our operating results.
-----------------------------------------------------------

In addition, stock markets have experienced extreme price and volume fluctuations. These fluctuations have especially affected the stock market price of many high technology and healthcare related companies, including pharmaceutical and biotechnology companies, and, in many cases, are unrelated to the operating performance of the particular companies. Market fluctuations, as well as general political and economic conditions, such as a